Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;4(1):25-32.
doi: 10.1007/s11899-009-0004-7.

Do we know more about essential thrombocythemia because of JAK2V617F?

Affiliations
Review

Do we know more about essential thrombocythemia because of JAK2V617F?

Claire Harrison. Curr Hematol Malig Rep. 2009 Jan.

Abstract

The discovery of the JAK2V617F mutation has triggered enormous interest and some progress in our understanding of the pathogenesis of myeloproliferative disorders. This article reviews its impact upon our knowledge regarding essential thrombocythemia. The discovery of JAK2V617F has led to the proposal that essential thrombocythemia, polycythemia vera, and primary myelofibrosis be discarded as separate diagnoses, and the rationale for this change is discussed. Simplified diagnostic criteria based upon testing for JAK2V617F are proposed. Interesting data are emerging regarding disease progression and risk of complications, specifically thrombosis, pregnancy loss, and perhaps progression to myelofibrosis. The JAK2V617F allele burden is emerging as a potentially important risk factor, although its measurement is not yet standardized. It also may serve as a tool for monitoring the effects of emerging novel therapies, which hold the potential to revolutionize treatment, ranging from reducing risk of complications to potential cure. As with many important scientific discoveries, however, although the discovery of the JAK2V617F mutation has helped us to move forward, there are many new questions and many old questions still unanswered.

PubMed Disclaimer

References

    1. PLoS Med. 2006 Jul;3(7):e270 - PubMed
    1. Lancet. 2005 Mar 19-25;365(9464):1054-61 - PubMed
    1. Exp Hematol. 2007 Nov;35(11):1641-6 - PubMed
    1. Blood. 2008 Feb 1;111(3):1686-9 - PubMed
    1. Semin Cell Dev Biol. 2008 Aug;19(4):385-93 - PubMed

LinkOut - more resources